Form 4: Protagonist Therapeutics Executive Suneel Gupta Exercises Options and Sells Shares

Protagonist Therapeutics' Chief Development Officer, Suneel Gupta, exercised stock options and sold shares to cover the exercise costs.

Summary

• Suneel Gupta, Chief Development Officer at Protagonist Therapeutics, executed multiple transactions involving the company's stock.
• On November 25, 2024, Gupta exercised options to acquire 175,000 shares at prices of $7.38, $8.02 and $7.80 per share.
• Also on November 25, 2024, Gupta sold 103,437 shares at a weighted average price of $46.04 per share, with individual sales ranging from $45.63 to $46.50.
• On November 26, 2024, Gupta exercised options to acquire 30,450 shares at a price of $12.17 per share.
• On November 26, 2024, Gupta sold 19,191 shares at a weighted average price of $45.50 per share, with individual sales ranging from $45.23 to $45.81.
• Following these transactions, Gupta's direct holdings of common stock are 267,433 shares and 93,300 stock options.

Sentiment

Score: 5

Explanation: The document reflects routine insider transactions, which are neither positive nor negative for the company's outlook. It is a neutral event.

Industry Context

This is a standard Form 4 filing, which is common for executives exercising stock options and selling shares. It is a routine part of executive compensation and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• Executive stock option exercises and sales are a common practice across the biotechnology industry.
• The reported transactions are consistent with standard compensation practices for executives in publicly traded companies.
• The sale of shares to cover the cost of exercising options is a typical strategy to manage personal finances and tax obligations.

Stakeholder Impact

• The transactions may have a minor impact on the stock price due to the sale of shares by an executive.
• The transactions do not have a direct impact on employees, customers, or suppliers.

Key Dates

Keywords

Protagonist Therapeutics, Suneel Gupta, stock options, share sales, insider trading, Form 4, equity transactions